KYMR Q1 2021 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+445.6% YoY

Gross Profit

$19M100.0% margin

Operating Income

-$13M-70.4% margin

Net Income

-$13M-69.9% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+46.3%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$465M

Total Liabilities

$189M

Stockholders' Equity

$275M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$3M	+445.6%
Gross Profit	$19M	$3M	+445.6%
Operating Income	-$13M	-$11M	-17.1%
Net Income	-$13M	-$11M	-19.6%